(NASDAQ: XFOR) X4 Pharmaceuticals's forecast annual revenue growth rate of 37.6% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.66%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.06%.
X4 Pharmaceuticals's revenue in 2026 is $35,113,000.On average, 5 Wall Street analysts forecast XFOR's revenue for 2026 to be $744,995,989, with the lowest XFOR revenue forecast at $561,338,203, and the highest XFOR revenue forecast at $1,050,122,489. On average, 5 Wall Street analysts forecast XFOR's revenue for 2027 to be $667,714,247, with the lowest XFOR revenue forecast at $579,158,464, and the highest XFOR revenue forecast at $754,178,878.
In 2028, XFOR is forecast to generate $9,862,968,622 in revenue, with the lowest revenue forecast at $5,822,497,332 and the highest revenue forecast at $17,260,195,089.